• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of cancer care >Pharmacotherapy follow-up of key points in the safety of oral antineoplastic agents
【24h】

Pharmacotherapy follow-up of key points in the safety of oral antineoplastic agents

机译：药物治疗口腔抗肿瘤剂安全性的关键点随访

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We assessed the impact of a pharmacotherapy follow-up programme on key safety points [adverse events (AE) and drug administration] in outpatients treated with oral antineoplastic agents (OAA). We performed a comparative, interventional, quasi-experimental study of outpatients treated with OAA in a Spanish hospital to compare pre-intervention group patients (not monitored by pharmacists during 2011) with intervention group patients (prospectively monitored by pharmacists during 2013). AE data were collected from medical records. Follow-up was 6 months, and 249 patients were included (pre-intervention, 115; intervention, 134). After the first month, AE were detected in 86.5% of patients in the pre-intervention group and 80.6% of patients in the intervention group, P = 0.096. During the remaining months, 79.0% patients had at least one AE in the pre-intervention group compared with 78.0% in the intervention group, P = 0.431. AE were more prevalent with sorafenib and sunitinib. In total, 173 drug interactions were recorded (pre-intervention, 80; intervention, 93; P = 0.045). Drug interactions were more frequent with erlotinib and gefitinib; food interactions were more common with sorafenib and pazopanib. Our follow-up of cancer outpatients revealed a reduction in severe AE and major drug interactions, thus helping health professionals to monitor the safety of OAA.
机译：我们评估了药物治疗后续计划对用口服抗肿瘤剂（OAA）处理的关键安全点[不良事件（AE）和药物管理]的关键安全点[不良事件（AE）和药物管理]的影响。我们对西班牙医院中OAA治疗的门诊患者进行了比较，介入，准实验研究，以比较干预群患者（2011年药剂师未监测）治疗患者（2013年在2013年期间被药剂师监督）。从医疗记录中收集AE数据。随访时间为6个月，包括249名患者（预先介入，115;干预，134）。在第一个月后，在介入前组的86.5％的患者中检测到AE，80.6％的干预组患者，P = 0.096。在剩下的几个月中，79.0％的患者在预干预组中至少有一个AE，而干预组的78.0％，P = 0.431。与索拉非尼和桑顿林更普遍。总共记录了173种药物相互作用（前期前期，80;干预，93; P = 0.045）。用奥尔特替尼和吉替尼更频繁，药物相互作用更频繁;食物相互作用与索拉非尼和Pazopanib更常见。我们的癌症门诊患者的随访显示严重AE和主要药物互动的降低，从而帮助卫生专业人员监测OAA的安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号